BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 18226586)

  • 1. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.
    Sutter JA; Kwan-Morley J; Dunham J; Du YZ; Kamoun M; Albert D; Eisenberg RA; Luning Prak ET
    Clin Immunol; 2008 Mar; 126(3):282-90. PubMed ID: 18226586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
    Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
    Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.
    Anolik JH; Barnard J; Owen T; Zheng B; Kemshetti S; Looney RJ; Sanz I
    Arthritis Rheum; 2007 Sep; 56(9):3044-56. PubMed ID: 17763423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
    Anolik JH; Barnard J; Cappione A; Pugh-Bernard AE; Felgar RE; Looney RJ; Sanz I
    Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.
    Perrotta S; Locatelli F; La Manna A; Cennamo L; De Stefano P; Nobili B
    Br J Haematol; 2002 Feb; 116(2):465-7. PubMed ID: 11841453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.
    Dörner T; Kinnman N; Tak PP
    Pharmacol Ther; 2010 Mar; 125(3):464-75. PubMed ID: 20097226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
    Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
    J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG; Jones RB; Burns SM; Jayne DR
    Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: a promising therapy in systemic lupus erythematosus.
    Thatayatikom A; White AJ
    Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
    Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
    Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cell monitoring of transplant patients treated with anti-CD20.
    Abdallah KO; Prak ET
    Clin Transpl; 2006; ():427-37. PubMed ID: 18365400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.
    Anolik JH; Campbell D; Felgar RE; Young F; Sanz I; Rosenblatt J; Looney RJ
    Arthritis Rheum; 2003 Feb; 48(2):455-9. PubMed ID: 12571855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R; Albert D
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study.
    Dhir V; Singh AP; Aggarwal A; Naik S; Misra R
    Lupus; 2009 Aug; 18(9):785-91. PubMed ID: 19578102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
    Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
    Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.